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Simple Summary: Considering the spatiotemporal heterogeneity, more frequent monitoring of the
disease progress using less-invasive liquid biopsy technologies is highly desired. Here, we demonstrate
that epidermal growth factor receptor (EGFR) mutations could be readily detected from minimally
invasive bronchial washing (BW)-derived EVs with good accuracy. The acquisition of T790M resistance
mutation was detected earlier in BW-derived EVs than in plasma or tissue samples. The longitudinal
analysis of BW-derived EVs showed excellent correlation with the disease progression measured by
CT images. We demonstrate the clinical potential of BW-derived EVs as a liquid-biopsy sample for
prognosis and precision medicine in patients with lung cancer.
Abstract: The detection of epidermal growth factor receptor (EGFR) mutation, based on tissue biopsy
samples, provides a valuable guideline for the prognosis and precision medicine in patients with
lung cancer. In this study, we aimed to examine minimally invasive bronchial washing (BW)-derived
extracellular vesicles (EVs) for EGFR mutation analysis in patients with lung cancer. A lab-on-a-disc
equipped with a filter with 20-nm pore diameter, Exo-Disc, was used to enrich EVs in BW samples.
The overall detection sensitivity of EGFR mutations in 55 BW-derived samples was 89.7% and
31.0% for EV-derived DNA (EV-DNA) and EV-excluded cell free-DNA (EV-X-cfDNA), respectively,
with 100% specificity. The detection rate of T790M in 13 matched samples was 61.5%, 10.0%,
and 30.8% from BW-derived EV-DNA, plasma-derived cfDNA, and tissue samples, respectively.
The acquisition of T790M resistance mutation was detected earlier in BW-derived EVs than plasma
or tissue samples. The longitudinal analysis of BW-derived EVs showed excellent correlation with
the disease progression measured by CT images. The EGFR mutations can be readily detected in
BW-derived EVs, which demonstrates their clinical potential as a liquid-biopsy sample that may aid
precise management, including assessment of the treatment response and drug resistance in patients
with lung cancer.
Keywords: lung cancer; liquid biopsy; bronchial washing (BW); extracellular vesicles; EGFR; T790M
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1. Introduction
Lung cancer is one of the leading causes of cancer-related deaths worldwide, with the highest
cancer-related death rate [1–3]. Recent advances in precision medicine have had profound implications
on the diagnostics and treatment monitoring in patients with lung cancer [4–6]. The somatic mutations
found in cancer tissues strongly influence the patients′ survival rate, and the best treatment options
for individual patients can be determined by clinicians according to the molecular profiling of the
cancer [7–9].
Genetic mutation of epidermal growth factor receptor (EGFR) gene is one of the critical therapeutic
markers for lung cancer [10]. It is related to tyrosine kinase inhibitor (TKI)-associated drugs [11,12],
which inhibit the abnormal growth of tumor by reducing the binding of tyrosine kinase with EGFR in
the cancer cells. The T790M mutation of the EGFR tyrosine kinase domain constitutes a large portion of
resistance to these drugs. When the T790M mutation of the EGFR gene is timely detected, the resistance
to the TKI drug can be overcome by selecting alterative options to improve the outcomes of patients
with lung cancer [13–15].
Even better, liquid biopsy, which is now frequently used in non-invasive prenatal diagnostic test
area, is expanding toward the diagnosis and treatment in cancer. Liquid biopsy is relatively less invasive
and complementary to the tissue biopsy, which is invasive and sometimes not a feasible option in several
patients [16–18]. Various circulating biomarkers such as circulating tumor cells (CTCs), cell-free DNA
(cfDNA), and extracellular vesicles (EVs) have been used as source materials for the characterization of
tumors. EVs are small vesicles (30–1000 nm) surrounded by a lipid bilayer, secreted or protruded by the
cells [19,20]. It has been reported that EVs released by cancer tissues contain tumor-associated genetic
materials such as mRNA, DNA, and proteins [21–23]. While CTCs and cfDNA have been mainly
used for liquid biopsy applications [24–26], EVs can be potentially superior [27] because their contents
such as genetic materials could remain protected by its lipid bilayer [28,29]. EVs have been associated
with the intercellular communication and cancer metastasis [30,31]. Therefore, we hypothesize that
monitoring tumor-derived EVs can be an efficient way to obtain dynamic information on cancer
progression in patients undergoing therapy.
The current gold standard for detecting EGFR mutation in lung cancer patients in the clinic is
cell cytology using tissue biopsy samples [25,32]. Recently reported studies used EVs and cfDNA
for lung cancer detection via plasma obtained from patients [16,33]. Additionally, EGFR mutations
were detected from DNA obtained from EVs in bronchoalveolar lavage fluid (BALF) of non-small-cell
lung cancer (NSCLC) patients [34]. However, the current drawbacks of using BALF or plasma are
that BALF shows higher detection rate but is relatively invasive and thus not a routine procedure of
bronchoscopy [35], while plasma is less invasive but shows lower detection rate compared to BALF [34].
Flexible bronchoscopy (FB) is an essential step in the diagnosis of lung cancer. Many diagnostic
procedures using FB, including washing, brushing, bronchoalveolar lavage, or biopsy, have been used
in various combinations to improve the diagnostic yield of FB in patients with suspected lung cancer.
BALF is obtained by advancing the bronchoscope into an airway, instilling about 100–150 mL of sterile
saline, and then quickly aspirating the instilled saline into a specimen trap. Bronchial washing (BW)
samples are similar to BALF, but different in that they need smaller volume of sterile saline and do not
require that the bronchoscope be wedged [36]. BW is widely known as a safe method [37–39].
There are many methods for isolating EVs such as ultracentrifugation, immunoaffinity-based
isolation, size exclusion chromatography, and ultrafiltration [40]. In this study, we focused on the
BW samples for less invasive sampling and enriched EVs for more sensitive molecular detection of
EGFR mutations. Using a size-based EVs filtration method, we analyzed EV-derived DNA (EV-DNA)
and EV-excluded cell free-DNA (EV-X-cfDNA) from BW for the mutation detection in lung cancer.
EGFR mutations, including L858R, 19del, and T790M, were examined in both EV-DNA and EV-X-cfDNA
from BW samples. Furthermore, the detection rate of T790M in BW-derived EVs was compared with
that in tissue, and blood plasma-based samples.
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2. Results
2.1. Patients
From July 2018 to September 2019, 52 lung cancer patients were enrolled in this study. Among them,
26 patients were mutant-type and 26 patients were wild-type according to the clinical tissue-based
detection. The median age of patients was 66 (ranging from 39 to 89) years for mutant types and 68
(ranging from 50 to 81) years for wild types. The clinical information of all patients is listed in Table 1.
The 26 mutant-type cases showed 38.5% of L858R and 61.5% of 19del mutation based on histological
and pathological data. Four patients with L858R or 19del mutation showed acquired resistance to
EGFR-TKI according to tissue re-biopsy, during the TKI treatment. BW samples were collected from all
patients and used for EGFR mutation detection by separately isolating EV-DNA and EV-X-cfDNA.
Table 1. Patient’s clinical and pathological characteristics.
Characteristic (n = 52) Mutant Type (%)n = 26
Wild Type (%)
n = 26
Median age (range) 66 (39–89) 68 (50–81)
Sex
Male 10 (38.5) 24 (92.3)
Female 16 (61.5) 2 (7.7)
Histology
Adenocarcinoma 23 (88.5) 10 (38.5)
Squamous cell carcinoma 2 (7.7) 16 (61.5)
Non-small-cell lung carcinoma, NOS 1 1 (3.8) 0 (0)
EGFR mutation type
L858R 10 (38.5) 0 (0)
19del 16 (61.5) 0 (0)
Stage, n (%)
I 0 (0) 3 (11.5)
II 2 (7.7) 4 (15.4)
III 2 (7.7) 6 (23.1)
IV 22 (84.6) 11 (42.3)
Unknown 0 (0) 2 (7.7)
1 NOS, not otherwise specified.
2.2. Detection of EGFR Mutation in Bronchial Washing-Derived Samples
We enriched EV-DNA in BW samples (<4 mL) using Exo-Disc [41]. EV-X-cfDNA were collected
in the flow-through chamber of the device after the filtration of EVs. Then, EGFR mutation detection
was confirmed by real-time PCR and ddPCR by targeting L858R, 19del, and T790M using EV-DNA
and EV-X-cfDNA (Figure 1). To confirm that we could detect the EVs from the BW, 10 samples were
analyzed. After the isolation of EVs, their characteristics were confirmed using size, shape, and indirect
enzyme-linked immunosorbent assays (ELISA) to measure EV markers such as tetraspanins CD9,
CD63, and CD81 (Figure 2). The average size of EVs was 205.1 ± 7.3 nm, and the particle concentration
was 1.7 × 1010–2.2 × 1011 particles/mL.
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Figure 1. Schematic illustration of experimental process. Bronchial washing (BW) samples are injected
into an Exo-Disc. Upon spinning the disc, the liquid flow through the filter that is in tangential direction
with the centrifugal force minimizing the clogging issue. The extracellular vesicles (EVs) are enriched on
top of the filter by size-based isolation and the flow-through liquid is used to analyze the EV-excluded
cell free DNA. The EGFR mutation is confirmed by Polymerase Chain Reaction.
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 Figure 2. Characterization of extracellular vesicles (EVs): (A) size distribution and concentration of
EVs measured by Nanoparticle Tracking Analysis; (B) EVs were confirmed by ELISA using CD9, CD63,
and CD81 markers; and (C) scanning electron microscope and (D) transmission electron microscope
images of bronchial washing-derived-EVs.
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In total, 55 BW samples from 52 patients having 29 mutant and 26 wild type results from tissue
samples were subject of the study to prepare EV-DNA and EV-X-cfDNA samples. As shown in Table 2,
of the 55 samples, the L858R and 19del EGFR mutations were identified by real time PCR in 26 EV-DNA
samples and 9 EV-X-cfDNA samples, respectively. The wild-type EGFR was detected in 26 EV-DNA
and 26 EV-X-cfDNA samples. Therefore, the EGFR mutation detection sensitivity was 89.7% and 31%
from EV-DNA and EV-X-cfDNA, respectively, with 100% specificity in both groups.
Table 2. Detection rate of EGFR mutation by real time PCR using bronchial washing sample; EV-DNA
and EV-excluded-cell free DNA (EV-X-cfDNA) from bronchial washing sample.
EGFR Mutation Tissue
BW (n = 55)
EV-DNA EV-X-cfDNA
Mutant 29 26 9
Wild 26 26 26
Sensitivity 89.7% 31.0%
Specificity 100% 100%
2.3. EGFR T790M Mutation Detection in Bronchial Washing-Derived, Plasma, and Tissue Samples
We tested EGFR T790M mutation in BW-derived EV-DNA by ddPCR and compared that with the
corresponding tissue samples and cfDNA derived from plasma in 11 patients. As shown in Figure 3A,
EGFR T790M mutations were identified in eight BW EV-DNA samples, while only one case from blood
plasma derived cfDNA and four tissue samples showed T790M mutations. Therefore, the T790M
detection rate was 61.5%, 10.0%, and 30.8% in BW-derived EV-DNA, cfDNA from plasma, and tissues,
respectively. Notably, eight cases of acquired T790M mutation were detected among 11 patients
via the BW-derived EV-DNA samples, including those four patients whose tissue sample showed
the T790M mutation (P6, P7, P8, and P11). In Patient 6, the acquired T790M was detected via all
samples, i.e., BW-derived EV, blood plasma cfDNA, and tissue samples. Furthermore, L858R and
19del EGFR mutations were identified by ddPCR in 11 BW-derived EVs and the corresponding
tissue samples, which resulted in 100% sensitivity. Conversely, in the case of plasma-derived cfDNA,
three of 10 available samples were false negative (P5, P7, and P9) in the detection of L858R and 19del
EGFR mutations, which resulted in 70% sensitivity. When we compared the number of copies of the
EGFR mutations (L858R and 19del) found in 13 BW-derived EV-DNA samples and the corresponding
tumor size measured from CT scan images, there was weak positive correlation (Figure S1).
We repeated the tests using the available samples from the patients who showed the acquired
T790M mutation in only BW EV-DNA samples but not in the tissue samples (P2 and P5-1). In the cases
of P1-1 and P9, the follow-up samples were not available because of the death or transfer to other
hospital. In Patient 2, the T790M mutation could be detected in BW EV-DNA sample initially but not
in both the tissue and blood plasma derived cfDNA samples (P2). After three months (P2-1), however,
the T790M mutation could be detected in the plasma cfDNA samples, confirming the earlier detection
of T790M from the BW EV-DNA samples (Figure 3B). CT scan images showed that the tumor size
slightly increased from 9.0 (P2) to 9.6 cm (P2-1) during the three months (Figure 3C). The corresponding
tissue sample after three months could not be achieved because of the patient′s condition.
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Figure 3. Detection of original mutations (L858R, 19del) and acquired T790M by ddPCR in BW-derived
EV-DNA with plasma-derived cfDNA and tissue samples. (A) In 11 patients with re-biopsy samples,
T790M was detected in 61.5%, 10%, and 30.8% of EV-DNA in BW, cfDNA of plasma, and tissues,
respectively. Patients 1 (P1) and 5 (P5) were included in the longitudinal study and additional samples
were collected after four and eight months for P1 (P1-1) and P5 (P5-1), respectively. (B–E) In samples
of P2 (B,C) and P5-1 (D,E), T790M was detected in BW-derived EV-DNA samples but not in tissue
samples. After three or four months, the acquired T790M mutation was detected from plasma cfDNA
(P2-1) and both from plasma cfDNA and tissue re-biopsy samples (P5-2), respectively. CT scan images
showed that the tumor size slightly increased (C) from 9.0 (P2) to 9.6 cm (P2-1) and (E) from 7.1 (P5-1)
to 7.3 cm (P5-2) during the three and four months for P2 and P5-1, respectively.
Similarly, the 19del mutation was identified in both BW EV-DNA and tissue samples but not
in plasma-derived cfDNA in Patient 5 (P5). Four months later, the 19del EGFR mutations could be
detected from all of the sa ples, while the T790M mutation was detected only in BW EV-DNA sampl s
(P5-1) but not in plasma cfDNA and tiss samples. However, four months later (P5-2), t T790M
mutations wer detected from both plasma-derived cfDNA and the corresponding tissu s samples,
which confirmed the earl er detection of T790M mutation in BW EV-DNA samples than plasma cfDNA
or tissue samples (Figure 3D). CT scan images showed tha the tumor size slightly increased from
7.1 (P5-1) to 7.3 cm (P5-2) du ing the f ur months (Figure 3E).
2.4. Monitoring of EGFR Mutation during Targeted Therapy
In the longitudinal monitoring of BW-derived EV-DNA samples performed in a blind manner,
we observed meaningful prognostic value of BW-derived EV-DNA-based genotyping. The number of
copies of the EGFR mutations found in BW-derived EV-DNA from a 61-year-old male (P 5), who had
stage IIIB, SCC with 19del mutation, increased from 72 to 3466.7 copies/mL for the 19del mutation,
and fro 0 to 85.3 copies/mL for the T790M mutation, respectively (Figure 4A,B). While the primary
tumor size decreased from 8.3 to 7.1 cm during the four-month period of monitoring, additional
CT image taken afterwards could confirm the presence of a new metastasis in the brain. In this
example, the increase of the EGFR T790M mutation in EV-DNA from the BW-derived sample could be
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detected even though the primary tumor size in the CT image was decreased, which was much earlier
than the CT image could identify the metastasis to the brain. In another case (P 1) of longitudinal
monitoring of BW-derived samples, ddPCR data showed the increase of EGFR L858R mutations,
and the emergence of T790M mutations. The L858R mutation increased from 499.2 to 520 copies/mL,
and the T790M mutation emerged from 0 to 6.8 copies/mL, respectively (Figure 4C,D). As we checked
the corresponding patients’ information, we learned that the BW samples were from a 52-year-old
female with stage IVB of adenocarcinoma with L858R mutation. According to the CT images taken
about eight months after the diagnosis, the tumor size increased from 3.7 to 5.6 cm. In both patients,
the treatment was changed from afatinib to osimertinib after the resistance gene T790M was detected.Cancers 2020, 12, x FOR PEER REVIEW 7 of 12 
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Figure 4. Monitoring of lung cancer patients via CT scan image and molecular analysis of EGFR
mutations by ddPCR of BW-derived EV-DNA. (A) The size of the tumor decreased from 8.3 (P5) to
7.1 cm (P5-1) after about four months. However, a new metastasized lesion was found in the brain.
(B) 19del EGFR mutation was increased and T790M EGFR mutation was emerged. (C) The tumor size
increased from 3.7 to 5.6 cm after eight months of TKI therapy. (D) The L858R EGFR mutation was
also increased, and T790M EGFR mutation emerged from ddPCR results of BW-derived EV-based
liquid biopsy.
3. Discussion
Sensitive and frequent genotyping of the EGFR mutation can benefit patients with NSCLC by
providing timely guidelines on the appropriate EGFR-targeted therapies. To the best of our knowledge,
this was the first study to report that EGFR mutations could be readily detected from BW-derived
EV-DNA samples with good accuracy (94.5%). The EGFR mutation detection sensitivity, 26/29 (89.7%),
that we achieved using BW-derived EV-DNA samples was slightly lower than the previous literature
report using more invasive BALF-derived EV-DNA samples, 14/14 (100%) [34]. However, it was higher
than the plasma-derived EV-DNA samples from patients with early stage 38/148 (26%), or late-stage
(~80%) NSCLC [42], demonstrating that the proximal fluid may more accurately represent the tumor
status. Although the BW-derived samples have been previously regarded as less sensitive compared
to BALF, our results show that BW-derived EVs can be an indispensable source for the liquid biopsy
considering the tumor contiguity, and because it is less invasive and can be performed with lower risk
for both the patient and clinician.
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This study had several potential limitations. First, this was a single-center study with available
samples from only 52 patients. Second, even though we tried to compare the detection rate of the
EGFR mutation from BW-derived EVs, plasma-derived cfDNA, and tissue samples, we could only
have 11 cases of perfectly matched samples among the 26 patients because the clinical samples were
not always available depending upon the health conditions of the patients. Third, we only tested the
selected mutations including 19del, L858R, and T790M mutations in EGFR. Fourth, it was a prospective
study, and we could not track the patients’ prognosis and overall survival time. Therefore, we could
not investigate the correlation between the mutation detected from BW-derived EVs and the response
to the therapy and their survival outcomes. Finally, we could collect liquid biopsy samples only
when the patients visited the hospital for their regular check-up and CT scan imaging, even though,
under ideal circumstances, the liquid biopsy could be performed more frequently.
4. Materials and Methods
4.1. Storage and Handling of Clinical Samples
In this prospective study, BW fluids were obtained through bronchoscopy with written informed
consent from all participants. BW samples were collected from patients diagnosed with non-small
cell lung cancer by a pathologist; samples from 26 patients who were EGFR-negative and 26 patients
who were EGFR-positive were collected. The study protocol was reviewed and approved by the
Institutional Review Board (IRB) of Pusan National University Hospital (IRB 1805-031-067). Samples
were centrifuged at 300× g for 10 min, 2000× g for 10 min at 4 ◦C to remove cell and debris, and stored
at −80 ◦C before use.
4.2. Bronchoscopy and Process of Bronchial Washing
The bronchoscopies were done trans-orally or trans-nasally using a flexible fiber-optic
bronchoscope (Olympus, Tokyo, Japan) after sedation with midazolam and fentanyl and were
examined by board-certified respiratory therapist. Oropharyngeal and laryngeal anesthesia was
induced by administrating 2 mL of nebulized 4% lidocaine before the bronchoscopy, followed by
spraying 1 mL of 2% topical lidocaine into the oral and nasal cavities. The bronchoscope was inserted
through the vocal cords, followed by instillation of 2% lidocaine solution into the trachea and bilateral
main bronchi through the working channel. After the initial exploration, bronchial washing samples
were collected by instilling 10 mL of sterile normal saline followed by immediate suction thereafter.
4.3. Isolation of Extracellular Vesicles
EVs were isolated using a previously described lab-on-a-disc platform, Exo-Disc [41,43,44]. Each
disc is composed of 6 sample chambers each of which is connected to an AAO membrane with 20 nm
pore size for highly efficient tangential flow filtration. BW sample was injected into the sample chamber
after a pre-filtration step using a 0.8 µm syringe filter. The disc was rotated at a speed of 500× g to
isolate EVs. The EV excluded BW sample was filtered out in flow-through chamber and collected
separately (Figure 1). Before washing, to remove free-floating DNA that remained outside of EVs,
EVs solution was incubated with 50 U DNase (Qiagen, Hilden, Germany) in phosphate buffered saline
(PBS) for 20 min at room temp (RT), and washed with PBS at 500× g, the isolated EVs were eluted in
100 µL of prefiltered PBS and used for downstream analysis.
4.4. Nanoparticle Tracking Analysis
Nanoparticle tracking analysis (NTA) was done using Nanosight NS 500 system
(Malvern Instruments, Malvern, UK) to measure the size distribution and concentration of EVs.
EV samples were gently resuspended and diluted with pre-filtered PBS according to the manufacturer’s
recommended concentration range (25–100 particles/frame). To ensure consistency, identical settings
were used for all measurements and the mean values were calculated after the quintuplet replicates.
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4.5. Confirmatory Indirect ELISA for Markers of Extracellular Vesicles
ELISA was performed using a 96-well plate (Corning Inc., Steuben County, NY, USA). EVs in PBS
(50 µL) were used to coat a well by incubating it overnight at 4 ◦C; 1% BSA (bovine serum albumin)
in PBS was treated at RT for 1 h to prevent nonspecific binding. After washing with 0.1% BSA-PBS
buffer, the plate was incubated with primary antibodies CD9 (Cat No. 555370, BD Pharminogen),
CD63 (Cat No. 556019), and CD81 (Cat No. 555675) in PBS at RT for 1 h. After washing three times with
the washing buffer, the plate underwent 1 h incubation with HRP-conjugated secondary antibodies at
RT. The plate was washed three times with washing buffer and incubated for 15 min at RT after adding
TMB solution. The stop solution was added, and the absorbance of each solution was measured using
the Infinite M200 plate reader (Tecan, Männedorf, Switzerland) at 450 nm.
4.6. DNA Isolation from Bronchial Wash Sample
For EV-DNA and EV-X-cfDNA isolation, EVs were isolated from 2–4 mL of bronchial wash
sample by Exo-Disc. The EV-X-cfDNA samples were collected from the flow-through chamber.
Allprep DNA/RNA kit (Qiagen, Hilden, Germany) and QIAamp circulating nucleic acid kit were used
to extract EV-DNA and EV-X-cfDNA, respectively.
4.7. Cell-free DNA Isolation from Plasma
Around 5 mL of blood was collected in an EDTA-treated tube. cfDNA was extracted from plasma
using Cobas® cfDNA Sample Preparation Kit (Roche Molecular Systems, Pleasanton, CA, USA).
Extracted DNA was examined to find mutations using the protocol for cfDNA, with Cobas® EGFR
Mutation assay.
4.8. Real-Time Polymerase Chain Reaction
For the mutation analysis, 19del, L858R, and T790M were confirmed by PANAMutyper EGFR
mutation detection kit (Panagene, Daejeon, Korea). Five microliters of DNA template, 19 µL mastermix,
and 1 µL Taq DNA polymerase were used. Polymerase chain reaction (PCR) amplification was
performed using the QuantStudio6 (Thermo Fisher Scientific, Waltham, MA, USA) per the following
protocol: 50 ◦C for 2 min and 95 ◦C for 15 min; 15 cycles 95 ◦C for 30 s, 70 ◦C for 20 s, and 63 ◦C for
1 min; 35 cycles of 95 ◦C for 10 s, 53 ◦C for 20 s, and 73 ◦C for 20 s; and then, for melting curve analysis,
followed by 95 ◦C for 15 min, 35 ◦C for 5 min, and 35 to 75 ◦C (increment 0.5 ◦C) for 3 s.
4.9. Droplet Digital PCR
L858R, 19del, and T790M mutations of the EGFR gene were detected by droplet digital PCR
(ddPCR). The samples were prepared in 20 µL of reaction volume, including 10 µL of ddPCR Super
Master Mix, 5 µL of DNA template, and 1 µL each of the primer/probe. The primer/probes were
purchased from Bio-Rad (BR186dHsaCP 2000019, 2000020, 2000021, 2000022, 2000039, and 2000040).
Droplets were generated using a QX200 droplet generator (Bio-Rad, Hercules, CA, USA) using 70 µL of
oil. Master cycler pro S (Eppendorf, Hamburg, Germany) was used for PCR amplification employing
the following protocol: 95 ◦C for 10 min; 40 cycles of 94 ◦C for 30 s, 58 ◦C for 1 min, and 98 ◦C for
10 min; and then held at 4 ◦C. The fluorescence signal was measured with a QX200 droplet reader
(Bio-Rad) and analyzed by QuantaSoft software (Bio-Rad).
4.10. Scanning Electron Microscope Imaging
Each membrane with the enriched EVs was fixed using 4% paraformaldehyde in PBS at RT for
20 min. Subsequently, the surface of each membrane was washed once with PBS and went through
serial dehydration steps with 50%, 70%, 90%, and 100% of ethanol for 10 min each. Finally, 100% ethanol
treatment was repeated once again and dried at RT. The EVs fixed on the membrane were attached to
the sample holder with carbon paste, and the surface was coated with Pt by sputter. The scanning
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electron microscope (SEM) images of EVs were acquired with SU-8220 cold FE-SEM instrument
(Hitachi high technologies, Tokyo, Japan).
4.11. Bio-Transmission Electron Microscope Imaging
EVs were fixed with 4% formaldehyde after isolation and then fixed EVs were dropped on the
pre-cleaned parafilm. Poly-L-Lysine (PLL) coated formvar/carbon film grids were flipped on the
drop to absorb the sample. After flipping the grids upside down, they were dried at RT for 30 min.
The dried samples were stained with 10 µL of uranyless EM Stain for 1 min. The remaining solutions
were absorbed by paper and then dried. The image was taken by JEM-1400 Bio-Transmission Electron
Microscope (JEOL, Tokyo, Japan).
5. Conclusions
We demonstrated that BW-derived EVs could be used for accurate and frequent genotyping of
EGFR mutation in patients with NSCLC, and for early detection of actionable mutations for appropriate
therapy selection and monitoring of disease progression. Emerging T790M mutation could be detected
from BW-derived EV-DNA samples with superior detection rate to that in blood plasma-derived
cfDNA or tissue biopsy samples. Considering the importance of the early detection of T790M, which is
the marker related with TKI-related drug resistance, we carefully raise the necessity that a larger study
with EV-DNA from BW-derived samples may prove to be a more effective way of mutation detection to
predict and monitor the patients’ response to treatment and suggest appropriate treatment change in
the therapeutic regimen. Overall, we anticipate that the liquid biopsy using BW-derived EVs, enriched
by using Exo-Disc, may promote frequent monitoring of tumor progression and contribute to the
broader application of personalized medicine.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/10/2822/s1,
Figure S1: The number of copies of the EGFR mutations (L858R and 19del) found in 13 BW-derived EV-DNA
samples and the corresponding tumor size measured from CT scan images
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